AWP
VRTX icon

Abacus Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Abacus Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$783K Buy
1,753
+115
+7% +$53.6K 0.07% 138
2025
Q4 		$743K Buy
+1,638
New +$706K 0.07% 142

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Abacus Wealth Partners's VRTX Position: Q1 2026 in Review

Abacus Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 7% in Q1 2026, buying an estimated $53.6K and bringing the position to 1,753 shares worth $783K. The position accounts for 0.07% of the portfolio, ranked #138.

Abacus Wealth Partners first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Abacus Wealth Partners held 1,753 shares of Vertex Pharmaceuticals worth $783K as of Q1 2026.
  • Abacus Wealth Partners bought 115 Vertex Pharmaceuticals shares in Q1 2026, an estimated $53.6K.
  • Vertex Pharmaceuticals made up 0.07% of Abacus Wealth Partners's portfolio in Q1 2026, its #138 holding.
  • Abacus Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Abacus Wealth Partners's 13F filing for Q1 2026, filed 24 Apr 2026.